Significant Ownership of Ikarian Capital, LLC

Signature - Title
/s/ Neil Shahrestani - Neil Shahrestani, Sole Manager
Location
Dallas, TX
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Ikarian Capital, LLC.

Follow Filing Activity

Follow Ikarian Capital, LLC and return when a new Schedule 13D/G filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sign up to follow filing activity

Sponsored

Significant Ownership of Ikarian Capital, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TENX Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share 16% $6,473,244 967,600 0% Ikarian Capital, LLC 30 Nov 2025
QNRX Quoin Pharmaceuticals, Ltd. American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share 13% $3,052,472 211,538 0% Ikarian Capital, LLC 31 Jan 2026
SPRB Spruce Biosciences Inc. Common Stock, par value $0.0001 per share 11% $1,060,227 121,356 0% Ikarian Capital, LLC 31 Oct 2025
NXTC NextCure, Inc. Common Stock, $0.001 par value per share 10% $4,715,825 363,035 Ikarian Capital, LLC 31 Dec 2025
TRAW Traws Pharma, Inc. Common stock, par value $.01 per share 10% $1,308,164 +$359,065 812,524 +38% Ikarian Capital, LLC 31 Dec 2025
GRTX Galera Therapeutics, Inc. Common Stock, $0.001 par value per share 10% $376,934 7,538,690 Ikarian Capital, LLC 31 Dec 2024
CNTB Connect Biopharma Holdings Limited Ordinary Shares, par value $0.000174 per Share 8.8% $13,910,809 4,933,086 Ikarian Capital, LLC 31 Dec 2025
PTHS Pelthos Therapeutics Inc. Common Stock, par value $0.0001 per share 8.4% $6,534,617 +$1,771,892 255,758 +37% Ikarian Capital, LLC 31 Dec 2025
CHRO Channel Therapeutics Corp Common Stock, par value $0.0001 per share 7.3% $564,287 440,849 Ikarian Capital, LLC 31 Dec 2024
KZIA Kazia Therapeutics Limited American Depositary Shares, each representing five-hundred Ordinary Shares 5.1% $3,740,056 580,754 Ikarian Capital, LLC 31 Dec 2025
FBRX Forte Biosciences, Inc. Common Stock, $0.001 par value 5% $6,516,387 +$89,063 617,667 +1.4% Ikarian Capital, LLC 30 Jun 2025
IBIO IBIO, Inc. Common Stock 5% $947,430 1,151,051 Ikarian Capital, LLC 30 Sep 2025
ACOG Alpha Cognition Inc. Common Shares, no par value 4.9% $6,865,684 +$574,548 1,056,259 +9.1% Ikarian Capital, LLC 31 Dec 2025
CPIX Cumberland Pharmaceuticals Inc. Common Stock, no par value 4.9% $3,545,020 730,932 Ikarian Capital, LLC 31 Mar 2025
RLMD Relmada Therapeutics, Inc. Common Stock, par value $0.001 par value per share 4.8% $7,122,152 3,543,359 Ikarian Capital, LLC 30 Sep 2025
GCTK Glucotrack, Inc. Common Stock, par value $0.001 per share 4.5% $175,071 45,830 Ikarian Capital, LLC 31 Dec 2025
ATXI Avenue Therapeutics, Inc. Common Stock 4.1% $86,341 -$6,059 130,820 -6.6% Ikarian Capital, LLC 31 Dec 2025
AVTX Avalo Therapeutics, Inc. Common Stock, $0.001 Par Value 3.8% $9,049,101 -$6,100,673 711,967 -40% Ikarian Capital, LLC 30 Sep 2025
AEMD Aethlon Medical, Inc. Common Stock, $0.001 par value per share 2% $5,685 -$449,150 15,366 -99% Ikarian Capital, LLC 30 Sep 2025
GLTO Galecto, Inc. Common Stock, $0.00001 par value per share 0.6% 335,710 +18% Ikarian Capital, LLC 28 Feb 2026

Schedules 13D/G Reported by Ikarian Capital, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sponsored